ReviewFrontiers in endocrinology2026
The diabetic retina-brain axis hypothesis in diabetic cognitive impairment: from pathophysiological mechanisms to therapeutic implications.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic cognitive impairment (DCI) is a frequent complication of diabetes that significantly reduces the quality of life of elderly patients and substantially increases the societal health-care burden. Recent epidemiological investigations have demonstrated that the severity of diabetic retinopathy (DR) is independently associated with a greater risk of cognitive dysfunction. To clarify the relationship between ocular and cerebral comorbidities in diabetes, this paper proposes the diabetic retina-brain axis hypothesis. By reviewing barrier dysfunction, neuroinflammation, and oxidative stress, we systematically present evidence that supports the involvement of the retina-brain axis in DCI and highlight the shared mechanisms that underlie retinal and cerebral damage in diabetes. Therapeutic strategies that target the retina-brain axis, such as hypoglycemic agents, antioxidants and neuroprotective interventions, provide benefits for retinal health and cognitive function. Investigating the mechanisms underlying this axis offers important insights for early diagnosis, prevention and treatment of DCI. Consequently, this research can guide the development of more effective interventions, for example by informing the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to protect both retinal microvasculature and neuronal integrity. Future research should prioritize elucidating the pathways of information transmission between the retina and the brain, and clarifying the molecular and cellular basis of these processes. This will provide theoretical support for the development of cross-organ collaborative protection strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.